Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies.

Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies.
复制标题

DOI:
10.3389/fimmu.2021.773352
复制
发表时间:
2021
影响因子:
7.3
通讯作者:
Coutant F
Coutant F
中科院分区:
医学2区
文献类型:
--
作者:
Nombel A;Fabien N;Coutant F

文献摘要

参考文献

被引文献

相似文献

抗mda5皮肌炎是一种罕见的全身性自身免疫性疾病,历史上在日本有临床淀粉样皮肌炎和危及生命的快速进行性肺间质性疾病的患者中有描述。随后,该疾病的完整临床谱被皮肤、关节和血管表现所丰富。根据这些症状的优势,现在定义了三种不同的临床表型和不同的预后。迄今为止,这三种实体唯一已知的分子成分是靶向MDA5的特异性抗体,MDA5是抗病毒宿主免疫反应所必需的细胞质蛋白。已经出现了几种检测这些抗体的生物工具,每种工具都有缺点和局限性。然而,这种疾病的高度特异性血清学标记物的鉴定提出了其在发病机制中的作用的问题。尽管目前关于该病发病机制的知识仍处于初级阶段,但有几条证据支持干扰素介导的血管病变在皮肤和肺部病变的发展中发挥核心作用,以及抗mda5抗体可能参与的致病作用。在这里,我们回顾了支持这些假设的临床和生物学证据,并讨论了新兴疗法的贡献,这些疗法揭示了该疾病的发病机制。
Anti-MDA5 dermatomyositis is a rare systemic autoimmune disease, historically described in Japanese patients with clinically amyopathic dermatomyositis and life-threatening rapidly progressive interstitial lung disease. Subsequently, the complete clinical spectrum of the disease was enriched by skin, articular and vascular manifestations. Depending on the predominance of these symptoms, three distinct clinical phenotypes with different prognosis are now defined. To date, the only known molecular component shared by the three entities are specific antibodies targeting MDA5, a cytosolic protein essential for antiviral host immune responses. Several biological tools have emerged to detect these antibodies, with drawbacks and limitations for each of them. However, the identification of this highly specific serological marker of the disease raises the question of its role in the pathogenesis. Although current knowledge on the pathogenic mechanisms that take place in the disease are still in their enfancy, several lines of evidence support a central role of interferon-mediated vasculopathy in the development of skin and lung lesions, as well as a possible pathogenic involvement of anti-MDA5 antibodies. Here, we review the clinical and biological evidences in favor of these hypothesis, and we discuss the contribution of emerging therapies that shed some light on the pathogenesis of the disease.
危及生命的Covid-19患者中针对I型IFN的自身抗体。
DOI: 10.1126/science.abd4585
发表时间: 2020-10-23
期刊: Science (New York, N.Y.)
影响因子: --
作者:
Bastard P;Rosen LB;Zhang Q;Michailidis E;Hoffmann HH;Zhang Y;Dorgham K;Philippot Q;Rosain J;Béziat V;Manry J;Shaw E;Haljasmägi L;Peterson P;Lorenzo L;Bizien L;Trouillet-Assant S;Dobbs K;de Jesus AA;Belot A;Kallaste A;Catherinot E;Tandjaoui-Lambiotte Y;Le Pen J;Kerner G;Bigio B;Seeleuthner Y;Yang R;Bolze A;Spaan AN;Delmonte OM;Abers MS;Aiuti A;Casari G;Lampasona V;Piemonti L;Ciceri F;Bilguvar K;Lifton RP;Vasse M;Smadja DM;Migaud M;Hadjadj J;Terrier B;Duffy D;Quintana-Murci L;van de Beek D;Roussel L;Vinh DC;Tangye SG;Haerynck F;Dalmau D;Martinez-Picado J;Brodin P;Nussenzweig MC;Boisson-Dupuis S;Rodríguez-Gallego C;Vogt G;Mogensen TH;Oler AJ;Gu J;Burbelo PD;Cohen JI;Biondi A;Bettini LR;D'Angio M;Bonfanti P;Rossignol P;Mayaux J;Rieux-Laucat F;Husebye ES;Fusco F;Ursini MV;Imberti L;Sottini A;Paghera S;Quiros-Roldan E;Rossi C;Castagnoli R;Montagna D;Licari A;Marseglia GL;Duval X;Ghosn J;HGID Lab;NIAID-USUHS Immune Response to COVID Group;COVID Clinicians;COVID-STORM Clinicians;Imagine COVID Group;French COVID Cohort Study Group;Milieu Intérieur Consortium;CoV-Contact Cohort;Amsterdam UMC Covid-19 Biobank;COVID Human Genetic Effort;Tsang JS;Goldbach-Mansky R;Kisand K;Lionakis MS;Puel A;Zhang SY;Holland SM;Gorochov G;Jouanguy E;Rice CM;Cobat A;Notarangelo LD;Abel L;Su HC;Casanova JL
通讯作者: Casanova JL
抗 MDA5 抗体与 A/SIP 和外周血 T 细胞减少相关,可预测中国皮肌炎患者 ILD 的不良预后
DOI: 10.1007/s00296-011-2323-y
发表时间: 2012-12-01
影响因子: 4
作者:
Chen, Fang;Wang, Dongxue;Wang, Guochun
通讯作者: Wang, Guochun
DOI: 10.1002/art.39753
发表时间: 2016-11
影响因子: 13.3
作者:
Deakin, Claire T.;Yasin, Shireena A.;Simou, Stefania;Arnold, Katie A.;Tansley, Sarah L.;Betteridge, Zoe E.;McHugh, Neil J.;Varsani, Hemlata;Holton, Janice L.;Jacques, Thomas S.;Pilkington, Clarissa A.;Nistala, Kiran;Wedderburn, Lucy R.
通讯作者: Wedderburn, Lucy R.
内皮细胞损伤如何开始?内皮素在系统性硬化症中的作用。
DOI: 10.1186/ar2186
发表时间: 2007
影响因子: 4.9
作者:
Abraham, David;Distler, Oliver
通讯作者: Distler, Oliver
DOI: 10.1016/j.ajpath.2015.11.010
发表时间: 2016-03-01
影响因子: 6
作者:
Allenbach, Yves;Leroux, Gaelle;Stenzel, Werner
通讯作者: Stenzel, Werner